ReviewEuropean respiratory review : an official journal of the European Respiratory Society2016
Future perspectives in pulmonary arterial hypertension.
Review in European respiratory review : an official journal of the European Respiratory Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Identifying Key Biomarkers in Pediatric Pulmonary Hypertension: An Investigative Approach.Children (Basel, Switzerland) · 2024Article
- Long-term trends in the burden of pulmonary arterial hypertension in China and worldwide: new insights based on GBD 2021.Frontiers in medicine · 2024Article
- RELMα Licenses Macrophages for Damage-Associated Molecular Pattern Activation to Instigate Pulmonary Vascular Remodeling.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Pulmonary arterial hypertension: tailoring treatment to risk in the current era.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Putting skin in the game: dermis-derived stem cells provide insight into familial pulmonary hypertension.Stem cell investigation · 2017Article
- The revolution of pulmonary arterial hypertension.European respiratory review : an official journal of the European Respiratory Society · 2016Article
- The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series).Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While there have been advances in the field of pulmonary arterial hypertension (PAH), disease management remains suboptimal for many patients. The development of novel treatments and strategies can provide opportunities to target other mechanisms that play a role in the complex pathobiology of PAH outside of the three main pathophysiological pathways. In this review, we highlight some of the potential PAH therapies or techniques that are being, or have been, investigated in phase II clinical trials. This review also discusses potential points for consideration in the development of novel therapies that target putative disease mediators or modifiers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.